vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是RESOURCES CONNECTION, INC.的1.3倍（$152.6M vs $117.7M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -10.8%，领先45.3%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs -19.2%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $15.6M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -11.8%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
CPRX vs RGP — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $117.7M |
| 净利润 | $52.7M | $-12.7M |
| 毛利率 | 82.9% | 37.1% |
| 营业利润率 | 40.5% | -10.3% |
| 净利率 | 34.5% | -10.8% |
| 营收同比 | 7.6% | -19.2% |
| 净利润同比 | -5.8% | 81.6% |
| 每股收益（稀释后） | $0.40 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $117.7M | ||
| Q3 25 | $148.4M | $120.2M | ||
| Q2 25 | $146.6M | $139.3M | ||
| Q1 25 | $141.4M | $129.4M | ||
| Q4 24 | $141.8M | $145.6M | ||
| Q3 24 | $128.7M | $136.9M | ||
| Q2 24 | $122.7M | $148.2M | ||
| Q1 24 | $98.5M | $151.3M |
| Q4 25 | $52.7M | $-12.7M | ||
| Q3 25 | $52.8M | $-2.4M | ||
| Q2 25 | $52.1M | $-73.3M | ||
| Q1 25 | $56.7M | $-44.1M | ||
| Q4 24 | $55.9M | $-68.7M | ||
| Q3 24 | $43.9M | $-5.7M | ||
| Q2 24 | $40.8M | $10.5M | ||
| Q1 24 | $23.3M | $2.5M |
| Q4 25 | 82.9% | 37.1% | ||
| Q3 25 | 84.7% | 39.5% | ||
| Q2 25 | 85.9% | 40.2% | ||
| Q1 25 | 87.3% | 35.1% | ||
| Q4 24 | 84.7% | 38.5% | ||
| Q3 24 | 85.0% | 36.5% | ||
| Q2 24 | 87.4% | 40.2% | ||
| Q1 24 | 87.3% | 37.0% |
| Q4 25 | 40.5% | -10.3% | ||
| Q3 25 | 44.7% | -1.7% | ||
| Q2 25 | 45.2% | -47.0% | ||
| Q1 25 | 44.8% | -38.4% | ||
| Q4 24 | 44.3% | -52.7% | ||
| Q3 24 | 39.6% | -3.5% | ||
| Q2 24 | 44.2% | 7.6% | ||
| Q1 24 | 27.5% | 2.8% |
| Q4 25 | 34.5% | -10.8% | ||
| Q3 25 | 35.6% | -2.0% | ||
| Q2 25 | 35.6% | -52.6% | ||
| Q1 25 | 40.1% | -34.0% | ||
| Q4 24 | 39.4% | -47.2% | ||
| Q3 24 | 34.1% | -4.2% | ||
| Q2 24 | 33.2% | 7.1% | ||
| Q1 24 | 23.6% | 1.7% |
| Q4 25 | $0.40 | $-0.38 | ||
| Q3 25 | $0.42 | $-0.07 | ||
| Q2 25 | $0.41 | $-2.21 | ||
| Q1 25 | $0.45 | $-1.34 | ||
| Q4 24 | $0.44 | $-2.08 | ||
| Q3 24 | $0.35 | $-0.17 | ||
| Q2 24 | $0.33 | $0.31 | ||
| Q1 24 | $0.19 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $194.6M |
| 总资产 | $1.1B | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $89.8M | ||
| Q3 25 | $689.9M | $77.5M | ||
| Q2 25 | $652.8M | $86.1M | ||
| Q1 25 | $580.7M | $72.5M | ||
| Q4 24 | $517.6M | $78.2M | ||
| Q3 24 | $442.3M | $89.6M | ||
| Q2 24 | $375.7M | $108.9M | ||
| Q1 24 | $310.4M | $113.8M |
| Q4 25 | $954.3M | $194.6M | ||
| Q3 25 | $920.2M | $206.4M | ||
| Q2 25 | $856.0M | $207.1M | ||
| Q1 25 | $794.3M | $277.8M | ||
| Q4 24 | $727.6M | $325.7M | ||
| Q3 24 | $660.9M | $407.2M | ||
| Q2 24 | $608.7M | $418.8M | ||
| Q1 24 | $561.4M | $414.9M |
| Q4 25 | $1.1B | $289.3M | ||
| Q3 25 | $1.1B | $287.2M | ||
| Q2 25 | $971.9M | $304.7M | ||
| Q1 25 | $908.9M | $375.6M | ||
| Q4 24 | $851.4M | $424.9M | ||
| Q3 24 | $772.0M | $512.9M | ||
| Q2 24 | $706.4M | $510.9M | ||
| Q1 24 | $646.7M | $523.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $15.6M |
| 自由现金流率自由现金流/营收 | 29.4% | 13.2% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $24.3M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $15.9M | ||
| Q3 25 | $32.4M | $-7.8M | ||
| Q2 25 | $71.3M | $16.8M | ||
| Q1 25 | $60.0M | $659.0K | ||
| Q4 24 | $70.9M | $1.8M | ||
| Q3 24 | $72.9M | $-309.0K | ||
| Q2 24 | $64.1M | $3.2M | ||
| Q1 24 | $31.9M | $20.5M |
| Q4 25 | $44.9M | $15.6M | ||
| Q3 25 | — | $-8.0M | ||
| Q2 25 | $71.3M | $16.5M | ||
| Q1 25 | — | $238.0K | ||
| Q4 24 | $70.8M | $61.0K | ||
| Q3 24 | $72.6M | $-575.0K | ||
| Q2 24 | $64.1M | $3.0M | ||
| Q1 24 | $31.7M | $20.4M |
| Q4 25 | 29.4% | 13.2% | ||
| Q3 25 | — | -6.6% | ||
| Q2 25 | 48.6% | 11.8% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | 49.9% | 0.0% | ||
| Q3 24 | 56.4% | -0.4% | ||
| Q2 24 | 52.3% | 2.1% | ||
| Q1 24 | 32.2% | 13.5% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.1% | 1.2% | ||
| Q3 24 | 0.2% | 0.2% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.2% | 0.1% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | 0.30× | ||
| Q1 24 | 1.37× | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
